Literature DB >> 12833463

Telomere length variation and maintenance in hepatocarcinogenesis.

Takashi Yokota1, Takeshi Suda, Masato Igarashi, Takashi Kuroiwa, Nobuo Waguri, Hirokazu Kawai, Yusaku Mita, Yutaka Aoyagi.   

Abstract

BACKGROUND: Despite the recent discovery of interchromosomal telomere length variation, a role for heterogeneity in telomere maintenance has yet to be established. This study investigated the significance of telomere length variation between chromosomes with respect to the association of cancer progression and telomere length regulation.
METHODS: Terminal restriction fragment (TRF) was evaluated in 20 surgically resected hepatocellular carcinoma specimens (HCC), corresponding noncancerous liver tissue specimens (NCL), and in 10 liver tissue specimens with chronic liver diseases devoid of cancer (DOC). Average TRF length (TRF-A) was defined as the point of maximum intensity. Shorter and longer TRF lengths (TRF-S and TRF-L) were defined as the length above which 90% of TRF distribution was involved. A ratio, (TRF-L-TRF-S)/TRF-A, was defined as telomere length dispersion.
RESULTS: The dispersion was significantly larger in HCC than in NCL specimens (P = 0.012) and in NCL than in DOC (P = 0.048). TRF-A and TRF-S were significantly shorter in HCC than in NCL (P = 0.0026, P = 0.0010). In seven patients in whom HCC recurred within 1 year, TRF-A and TRF-S were significantly shorter than in 10 patients in whom recurrence occurred after 1 year (P = 0.018, P = 0.0097). Telomeric repeat binding factor 1 was up-regulated in HCC with elongated TRF-L, whereas expression of human telomerase reverse transcriptase was greater in HCC with a shorter TRF-S.
CONCLUSIONS: These results suggest that telomere length varied through chronic liver diseases by preferentially increasing shorter telomeres, whose length is a good indicator for malignant potential of HCC. Telomere length variation may be a crucial code in telomere maintenance through hepatocarcinogenesis. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11428

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833463     DOI: 10.1002/cncr.11428

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Relationship between microvessel density and telomerase activity in hepatocellular carcinoma.

Authors:  Yun-Feng Piao; Min He; Yang Shi; Tong-Yu Tang
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

2.  Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Han-Qiang Liu; Jia-Ze An; Juan Liu; Ye-Fa Yang; Hong-Xin Zhang; Bin-Yu Zhao; Ji-Bin Li; Hu-Shan Yang; Zhi-Nan Chen; Jin-Liang Xing
Journal:  Carcinogenesis       Date:  2012-02-08       Impact factor: 4.944

3.  Hepatocellular telomere length in biliary atresia measured by Q-FISH.

Authors:  Yukihiro Sanada; Junko Aida; Youichi Kawano; Ken-ichi Nakamura; Naotaka Shimomura; Naoshi Ishikawa; Tomio Arai; Steven S S Poon; Naoya Yamada; Noriki Okada; Taiichi Wakiya; Makoto Hayashida; Takeshi Saito; Satoshi Egami; Shuji Hishikawa; Yoshiyuki Ihara; Taizen Urahashi; Koichi Mizuta; Yoshikazu Yasuda; Hideo Kawarasaki; Kaiyo Takubo
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

4.  Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma.

Authors:  Deng-Fu Yao; Wei Wu; Min Yao; Li-Wei Qiu; Xin-Hua Wu; Xiao-Qin Su; Li Zou; Deng-Bing Yao; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

Review 5.  Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma.

Authors:  Ashraf Ali; Hany Abdel-Hafiz; Mohd Suhail; Amany Al-Mars; Mohammad Khalid Zakaria; Kaneez Fatima; Sultan Ahmad; Esam Azhar; Adeel Chaudhary; Ishtiaq Qadri
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 6.  Non-canonical roles of canonical telomere binding proteins in cancers.

Authors:  Semih Can Akincilar; Claire Hian Tzer Chan; Qin Feng Ng; Kerem Fidan; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

7.  Potential clinical role of telomere length in human glioblastoma.

Authors:  D La Torre; M Aguennouz; A Conti; M Giusa; G Raffa; R V Abbritti; A Germano'; F F Angileri
Journal:  Transl Med UniSa       Date:  2011-10-17

8.  Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States.

Authors:  Baiyu Yang; Fatma M Shebl; Lawrence R Sternberg; Andrew C Warner; David E Kleiner; Daniel C Edelman; Allison Gomez; Casey L Dagnall; Belynda D Hicks; Sean F Altekruse; Brenda Y Hernandez; Charles F Lynch; Paul S Meltzer; Katherine A McGlynn
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

9.  Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma.

Authors:  Li-Jie Ma; Xiao-Ying Wang; Meng Duan; Long-Zi Liu; Jie-Yi Shi; Liang-Qing Dong; Liu-Xiao Yang; Zhi-Chao Wang; Zhen-Bin Ding; Ai-Wu Ke; Ya Cao; Xiao-Ming Zhang; Jian Zhou; Jia Fan; Qiang Gao
Journal:  J Pathol       Date:  2017-10-13       Impact factor: 7.996

10.  Telomere length modulation in human astroglial brain tumors.

Authors:  Domenico La Torre; Alfredo Conti; M Hammed Aguennouz; Maria Grazia De Pasquale; Sara Romeo; Filippo Flavio Angileri; Salvatore Cardali; Chiara Tomasello; Concetta Alafaci; Antonino Germanò
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.